Cryopreservation of Equine Semen with a Mechanical Control Rate Freezer

Total Page:16

File Type:pdf, Size:1020Kb

Load more

CRYOPRESERVATION OF EQUINE SEMEN WITH A MECHANICAL
CONTROL RATE FREEZER

By
Sossi Marianne Iacovides, B.S.
A THESIS
IN
ANIMAL SCIENCE

Submitted to the Graduate Faculty of Texas Tech University in Partial
Fulfillment of the Requirements for the Degree of

MASTER OF SCIENCE
Approved

Dr. Samuel Prien

Chairperson

Dr. Samuel Jackson Dr. Leslie Thompson

Dr. Mark Sheridan
Dean of the Graduate School
December, 2014

Copyright 2014, Sossi Marianne Iacovides, B.S.

Texas Tech University, Sossi M. Iacovides, December 2014

ACKNOWLEDGMENTS

‘It’s hard to soar with eagles, if you won’t jump off the cliff.’ At the beginning of my graduate school process, I had the choice to start somewhere fresh and new. While it may have been the right move for some, it was not for me; I knew that I wasn’t finished with here. The Department of Animal & Food Sciences has become home, from the abundance of moral, ethical and personal support; it has been a blessing and privilege to spend the past 4 years here.
Dr. Glenn Blodgett, you believed in my research, and that means the world to me. Without the access to the 6666 Ranch, and your indispensible personnel, this project would have never gained flight. Mallory Canaday, the true “Swimmie Specialist,” you were an indispensable resource for me and I have learned more from you then I could have ever imagined. The lab personnel: my countless questions never went unanswered. I hope that you’ll walk the hallways and hear my snaughles forever more. The minions, my fellow graduate students, from the countless nights of studying, to the late night research – I could not have hoped for a better group to have survived these last two years with! Dr. Lindsey Penrose, where do I begin? You have been a foundation in my life since I began this journey. Your never-ending words of encouragement; the ideas we bounced back and forth; having been your chief minion in training…. You managed to keep this hot-blooded Greek girl off the edge! Can I finally have a (small) crown, Turtle Queen?!

ii

Texas Tech University, Sossi M. Iacovides, December 2014

Dr. Sam Jackson, starting with undergrad transfer orientation day, to sheep production and throughout my graduate career, you have always been available for help and encouragement. Thanks General. Dr. Leslie Thompson: I knew you would be a great asset after working with you for the IDEAL camps. Your crucial guidance in my exploration of your Alma Mater in Florida was invaluable, and I cannot thank you enough.
The Captain, Dr. Sam Prien: I don’t think it’s possible to sum up what you

mean to me in either a single word or even a few run on sentences. You have been so much more than just my mentor, confidant, and rock throughout my undergraduate and graduate careers. From presenting my research at different venues, to the times I have been at my wits end, I could not have made it this far without your endless understanding and support. I know my neon colors tend to get too bright and the shiny things too, but you put up with the true dark cutter and even managed to get a few songs out of it! You’re a phenomenal person, teacher and friend. Both you and your promise, “You will always have a home here,” will forever have a place in my mind and heart.
Girls, I don’t know how we all survived the past few years, but we

definitely kept each other sane. The ranch, if it wasn’t for the push you gave me years ago, I never would have made it this far following livestock as my passion. Mom, Mougs (and Chimmie) the late night phones calls; the crying over failed trials; the rejoicing when I finally finished. While I may sound like I’m speaking Chinese, you know the blood, sweat and tears that I poured into this. Thanks for iii

Texas Tech University, Sossi M. Iacovides, December 2014

putting up with my OCD, dark cutting ways and standing by my decisions to keep at it. A self-proclaimed perpetual student, without all of your help, I could not have lasted this long. But we did it! So the question is… Are y’all ready for the next 4 years?!
“You know what you gotta do when life gets you down? Just keep swimming, just keep swimming, just keep swimming, swimming, swimming!”
- Dory, Finding Nemo, Disney® (add a snaughle or two for good measure!)

iv

Texas Tech University, Sossi M. Iacovides, December 2014

TABLE OF CONTENTS

ACKNOWLEDGMENTS .................................................................................................. ii LIST OF TABLES .......................................................................................................... vi LIST OF FIGURES ........................................................................................................vii ABSTRACT ...............................................................................................................viii

CHAPTERS

I. LITERATURE REVIEW.................................................................................................. 1
HISTORY OF ARTIFICIAL INSEMINATION ...................................................................... 1 HISTORY OF CRYOPRESERVATION ............................................................................. 4 MULTI SPECIES INDUSTRY TRANSFORMATION ............................................................. 7 GENERAL CONCEPTS OF EQUINE SEMEN .................................................................. 11 TYPES OF EXTENDERS ........................................................................................... 19 CRYOPROTECTANT CLASSES ................................................................................... 25 FREEZING TECHNIQUES ........................................................................................ 34 STALLION SPERM PHYSIOLOGY & CRYOPRESERVATION ................................................ 37 THAWING: ISSUES & IMPROVEMENTS TO POST-THAW QUALITY.................................... 40 GENERAL DISCUSSION OF SPERM LOSS .................................................................... 42 FUTURE OF SEMEN CRYOPRESERVATION .................................................................. 48

II. CRYOPRESERVATION OF EQUINE SEMEN USING A MECHANICAL CONTROL RATE FREEZER..... 50

INTRODUCTION ................................................................................................... 50 MATERIALS & METHODS ...................................................................................... 52 SEMEN COLLECTION & PREPARATION ...................................................................... 52 SEMEN FREEZING ................................................................................................ 53 SEMEN THAWING ................................................................................................ 54 MORPHOLOGY & ACROSOMES............................................................................... 57 STATISTICAL ANALYSIS .......................................................................................... 58 RESULTS ............................................................................................................ 58 DISCUSSION ....................................................................................................... 81

III. CONCLUSION....................................................................................................... 83 LITERATURE CITED ..................................................................................................... 86 APPENDIX ................................................................................................................ 96

v

Texas Tech University, Sossi M. Iacovides, December 2014

LIST OF TABLES

1. COMPARISON OF INTERMEDIATE SPEED PARAMETERS BY TREATMENT & TIME ..................... 64 2. COMPARISON OF AVERAGE MOVEMENT CLASSIFICATIONS BY TREATMENT & TIME ............... 66

3. QUANTITATIVE COMPARISON OF TREATMENTS ............................................................. 80

4. PERCENT RETENTION OF CONCENTRATION, MOTILITY & RAPID CELLS ................................. 96

5. PERCENT RETENTION OF MORPHOLOGICAL VALUES ....................................................... 97 6. PERCENT RETENTION OF ACROSOME VALUES................................................................ 97

vi

Texas Tech University, Sossi M. Iacovides, December 2014

LIST OF FIGURES

1. COMPARISON OF CONCENTRATIONS BY TREATMENT & TIME ........................................... 60 2. COMPARISON OF MOTILITIES BY TREATMENT & TIME .................................................... 61

3. COMPARISON OF RAPID CELL PROGRESSION BY TREATMENT & TIME ................................. 62 4. COMPARISON OF NORMAL MORPHOLOGY BY TREATMENT & TIME .................................... 68 5. COMPARISON OF ABNORMAL HEAD MORPHOLOGY BY TREATMENT & TIME ........................ 70 6. COMPARISON OF ABNORMAL MIDPIECE MORPHOLOGY BY TREATMENT & TIME ................... 71 7. COMPARISON OF OTHER ABNORMAL TAIL MORPHOLOGY BY TREATMENT & TIME ................ 73 8. COMPARISON OF CURLED ABNORMAL TAIL MORPHOLOGY BY TREATMENT & TIME ............... 74

9. COMPARISON OF INTACT ACROSOMES BY TREATMENT & TIME ........................................ 76

10. COMPARISON OF PARTIALLY ACROSOMES BY TREATMENT & TIME .................................. 77 11. COMPARISON OF NON-INTACT ACROSOMES BY TREATMENT & TIME .............................. 78

vii

Texas Tech University, Sossi M. Iacovides, December 2014

ABSTRACT

With the evolving use of assisted reproductive technologies (ART) in the equine industry, there is a need for a cost effective, field method of preparing stallion semen for cryopreservation. Currently, semen is either suspended in the mist above liquid nitrogen or frozen in an electronic controlled rate freezer (ECRF). Mist freezing (VM) has an uncontrollable temperature drop, increasing damage to cells. ECRF yields superior results, yet is cost prohibitive and complex to use. The current study explored the use of a new mechanical controlled rate freezer (MCRF) in a control environment. Samples for cryopreservation where obtained from 15 stallions, and frozen using MF, ECRF or MCRF. Once thawed, the samples were analyzed for standard semen parameters using a computer assisted semen analyzer at 0 and 3 hours post thaw, additionally morphology and acrosome slides were prepared. Initial post-thaw analysis demonstrates rapid cell movement in both MCRF and ECRF; but not MF. Further, morphology from MCRF and ECRF correlate with stallion standards. With current data, the MCRF appears to produce higher quality samples than MF and comparable to ECRF.

viii

Texas Tech University, Sossi M. Iacovides, December 2014

CHAPTER I
LITERATURE REVIEW

History of Artificial Insemination

It has been widely reported that artificial insemination (AI) was first used in the twelfth century, but the accounts remain undocumented. In most reports, "negative AI” was used by Arab horseman, who bred selective mares to their enemies’ stallions. The irony was the mares were reported to have been artificially impregnated with the sperm of weak and inferior stallions, which introduced an impure breed strain into the line [1], being the opposite of our goals today. In a second account, which more closely mimics the definition of AI used today, an Arab chief stole semen from the stallion of rival so he could breed his mares to improve his own bloodlines [2]. With no document available to support these reports, credit for the first attempted use of AI is most often given to Spallanzani who attempted the process in the dog four centuries later, and thus earned him a permanent place in AI history [1].
Sperm were first described by Leeuwenhoek and his assistant, Hamm, in
1678 [3]. Referring to their discovery as ‘animacules,’ they were unaware of the importance of the discovery they had made. Yet their simple description has led to techniques allowing the manipulation of genetics in cattle, dogs, goats, horses, poultry, rabbits, sheep, swine, and endangered species [3]. Their discovery led to the AI experiments of Spallanzani; who performed AI in a dog

1

Texas Tech University, Sossi M. Iacovides, December 2014

model which resulted in the birth of three pups 62 days later [3]. Spallanzani capitalized on a concept, which may have been around for hundreds of years; he manipulated genetics through arguably the first assisted reproductive technology (ART) procedure and changed the ideologies of the current world. The discovery meant animals would no longer need to be ‘classically’ mated and led to a new wave of research. Yet it took over a century, until Heape in 1897 [4] and a variety of the other individuals from several countries, reported that AI had been used in isolated studies with rabbits, dogs, and horses [3].
Horses have always been a different and sometimes difficult species to work with, and such has been the case in the development of equine AI. With early domesticated horses being used for agriculture, and also military service, they were the first to be consistently worked with, for the betterment of their countries. In 1888, a French veterinarian, Repiquet, suggested AI to overcome subfertility in horses and cows, and later to breed more mares to one stallion, and to produce hybrid animals such as mules [5]. With WWI on the horizon, countries had already begun to explore his idea, and wanted to increase their equine military service forces at an expedited rate. Heape, described the aspiration of semen from bred mares, and used either a gelatin based capsule filled with semen or a syringe to transfer the semen to another mare’s uterus[5]. Later, G. Sand used porcine bladders as condoms to collect semen for breeding and birthed four foals from eight mares. Soon after, successful insemination of mares was reported across Europe from Austro-Hungarian Croatia, Hungary,
2

Texas Tech University, Sossi M. Iacovides, December 2014

and Russian Poland [5]. A Japanese scientist, Ishikawa, studied AI in Russia and upon his return to Japan began an equine insemination program in 1912 [5]. By the early 20th century, the AI was being practiced on a much larger scale, but little research had been done to explain the mechanics of the process.
While a number of researchers around the world were experimenting with AI, Russia had one of the active research programs. This was due in no small part to Nicholas II, the Russian Czar, who was aware of his country’s growing need for horses for the military service and agriculture and who recognized the potential for AI. He supported the scientist Elia Ivanov, who constructed the first controlled AI experiments and set a precedent for collecting horse semen [5]. With access to the Imperial Russian Studs, his research consisted of inserting silk sponges into mares, allowed them to be mounted, removing the sponge, collecting the semen with a press. He then used syringes to deposit the semen transcervically with a rubber tube into other mares [5]. In his published work, he systematically proved that he could use one stud to breed 500 mares, providing the documentation needing to move AI from an experimental protocol to farm procedure. Ivanov also discussed the idea of shipping semen to close locations and in 1912 provided an instructional booklet showing photographic evidence of foals on the ground to prove that there was no difference between the product of a natural breeding and one of AI [5]. He is also credited to be the first to use AI to produce interspecies hybrids in cattle, horses, poultry and zebroids by inseminating horse mares with zebra semen [5].
3

Texas Tech University, Sossi M. Iacovides, December 2014

Ivanov published his research in 1922, which included the development of some of the first semen extenders and training procedure for AI technicians. His work was followed in 1938 by Milovanov who created artificial vaginas (AV) and other items still use practically today[3]. The development of AV’s represented a monumental advancement in AI, it provided a superior method for collecting semen and results in less overall loss [3]. Western breeders remained unaware of these latest industry advancements, until Japanese researchers Niwa and Nishikawa summarized the recent works into English in 1958, 1962, 1964 and 1972 [3]. In 1933, Walton published a book on AI, which included a procedure for shipping ram semen and two days later using it to successfully inseminate ewes [3]. Danish veterinarians Sørensen & Gylling-Holm established cervix manipulation with rectovaginal fixation, a practice still used today, which required fewer sperm for insemination, as semen was deposited deep within the cervix into the uterine body[3].
Another advancement was the packaging of semen in straws. This was first done by Sørensen, who used hollowed oat straws until he serendipitously saw some made of cellophane at his daughter’s birthday [3]. This evolved into the commercial straws designed by Cassou in 1964 and still used worldwide today [3].

History of Cryopreservation

Cryopreservation (CP) is the ability to store cells and maintain their integrity and viability at a sub-zero temperature until needed. Like some of
4

Texas Tech University, Sossi M. Iacovides, December 2014

the greatest discoveries, CP was the result of a fortunate lab error. In 1949, Ernest John Christopher Polge and his colleagues were focused on trying to use sugars as cryoprotectant’s (CPO) using what they thought was a stock fructose solution [3]. They reported CP having been achieved with the fructose solution, however after chemical analysis of the bottle was completed, they realized it was all due to an error [3]. While history has provided varied accounts of the story, it is conclusive that due to the mislabeling of a solution bottle in a refrigerator, which led to fowl semen being frozen in a mixture of glycerol, albumen, and water [6]. This was clearly different from the intended solution of levulose, but allowing the fowl semen to be stored at -70oC, serendipitously discovering the first CPO [6]. By adding the glycerol, accidentally discovered by Polge et al. to a base media of yolk-citrate extender first described by Salisbury et al. in 1941, the first CPO was formed [3]. Later work would describe a variety of other CPO combinations, but the tris-buffered egg yolk-glycerol combination remains as a standard for the protection of frozen and unfrozen sperm [3].
Prior to Sørensen’s discovery of the straw as a vessel for the freezing and storage of semen, samples were frozen in glass ampules. This proved problematic at the time as samples were frozen using dry ice and the ampules would break during the freezing and thawing process [3]. However, with Cassou’s modified straw, and the 1974 discovery by Pickett and Berndtson of an efficient means for sealing plastic straws plus the AI gun for insemination [3], all processes were in place to all widespread use of the technology.
5

Texas Tech University, Sossi M. Iacovides, December 2014

When significant biological changes were observed (including a significant loss of fertility) in semen frozen and stored via solid carbon dioxide (−79°C), there was a shift towards liquid nitrogen −196°C, where sperm had be shown to survive with minimal biological changes [3]. A supporting factor pushing the shift to liquid nitrogen, was the lack of equipment necessary to maintain the dry ice, necessitating frequent resupply to maintain temperature. Because of the inferior insulation within the tanks of the day, this same issue was initially seen with liquid nitrogen. However, a motivated investor, named J. Rockefeller Prentice, who owned of American Breeders Service, convinced the Linde Division of the American Cyanamid Company that there was a market for liquid nitrogen containers with improved insulation, which has led to today’s nitrogen tanks [3].
The basic concept of CP is to reduce or if possible, avoid intracellular freezing, ice crystal formation, and to overall minimalize damage to the cell from the environment during cooling or freezing [7]. There are two different classes of cryoprotective agents (CPA), both of which have their own beneficial and disadvantageous properties in the world of CP. Each facilitates different binding potentials of molecules from both the penetrating and macromolecules (nonpentrating) solutions of which they are made [7]. The use of a CPA is not only species dependent, but also can depend heavily on the chemical composition of the male’s semen. The underlying purpose of a CPA is to increase the cell survival rates under (harsh) imposed conditions during CP [7].
6

Texas Tech University, Sossi M. Iacovides, December 2014

Current results indicate that penetrating and macromolecules agents accomplish this in different ways. Penetrating agents, such as dimethyl sulfoxide (DMSO), allow the manipulation of the cellular environment. Dimethyl sulfoxide encourages the reduction of cell water content, so at sufficiently low temperatures, it can reduce the damaging effect of the concentrated solutes on the cells [7]. Non-penetrating agents, the most common of which is glycerol, osmotically “squeeze” water from the cells primarily during the initial phases of freezing, when these additives become concentrated in the extracellular regions, with temperatures ranging −10 and −20 °C [7]. However the successful use of glycerol is heavily species dependent.

Multi Species Industry Transformation

The gains of reproductive technology are widespread throughout the animal industry, and the successful CP of spermatozoa has enabled growth of livestock breeding industry wide. The momentum gained from research has greatly reduced costs and enabled ART not only to change breeding practices in animal, but to become a practical reality in the treatment of human infertility [8]. Cryopreservation and cryobiology are multifaceted and a collaborative research effort between not only molecular biology and theriogenology, but also engineering and mathematics [8]. Due in part to the shape of sperm, the complex cytoskeletal structures, the cell’s molecular mechanism’s of activation and capacitation, there are a wide variety of applicable protocols from high tech laboratories to farm use [8]. Semen CP has helped to link all of these fields
7

Texas Tech University, Sossi M. Iacovides, December 2014

together for one common purpose: to further the superior genetics available for future generations.
As described earlier, the ability to freeze cattle semen, has turned out to be the specie that presents the fewest cryobiologic challenges, was discovered by accident, but by default became the starting point for semen preservation. As beef breed bull semen has been the least challenging to freeze efficiently, the general protocols for it have remained static for many years. Since CP is highly in demand with beef and dairy cattle, there has been an increase in the globalization of CP companies [8]. Yet, bovine semen post-thaw survival rates which use current methods range from 30%-40%, leaving much room for research to help improve CP technologies [8]. One notable modification was that of Purdy and Graham who investigated the effects of the additive cholesterol before CP and found that there was an increase in post-thaw motility in the cholesterol treated sperm when compared with control sperm [8]. However, the addition of cholesterol appeared to inhibited capacitation, which resulted in reduced fertility.
Sexed semen has added another dimension to the use of cryopreserved sperm within the cattle industry; especially with the dairy industry where cows represent potential income and bulls are generally an expense. However, it is well documented that the motility and concentration of semen from dairy bulls is considerably lower than that of beef cattle. Given that the number of sperm cells is significantly reduced when sexed, and with a lower recovery rate this
8

Recommended publications
  • Human Sperm Vitrification: the State of the Art Yong Tao*, Erika Sanger, Arpornrad Saewu and Marie-Claude Leveille

    Human Sperm Vitrification: the State of the Art Yong Tao*, Erika Sanger, Arpornrad Saewu and Marie-Claude Leveille

    Tao et al. Reproductive Biology and Endocrinology (2020) 18:17 https://doi.org/10.1186/s12958-020-00580-5 REVIEW Open Access Human sperm vitrification: the state of the art Yong Tao*, Erika Sanger, Arpornrad Saewu and Marie-Claude Leveille Abstract Sperm cryopreservation has been widely used in assisted reproductive technology (ART) and has resulted in millions of live births. Two principal approaches have been adopted: conventional (slow) freezing and vitrification. As a traditional technique, slow freezing has been successfully employed and widely used at ART clinics whereas the latter, a process to solidify liquid into an amorphous or glassy state, may become a faster alternative method of sperm cryopreservation with significant benefits in regard to simple equipment and applicability to fertility centers. Sperm vitrification has its own limitations. Firstly, small volume of load is usually plunged to liquid nitrogen to achieve high cooling rate, which makes large volume sample cryopreservation less feasible. Secondly, direct contact with liquid nitrogen increases the potential risk of contamination. Recently, new carriers have been developed to facilitate improved control over the volume and speed, and new strategies have been implemented to minimize the contamination risk. In summary, although sperm vitrification has not yet been applied in routine sperm cryopreservation, its potential as a standard procedure is growing. Keywords: Cryopreservation, Vitrification, Contamination, Liquid nitrogen, Spermatozoa, Semen Background births from frozen sperm after 4 decades storage in LN2 Over 8 decades ago, in 1938, Luyet and Hoddap per- had been reported [6]. Cryopreservation of spermatozoa formed the first vitrification of frog sperm in liquid air has been the most valuable and used way to preserve the [1].
  • Member Guide

    Member Guide

    MEMBER GUIDE Understanding Your Progyny Benefit 2019 PLAN YEAR YOUR GUIDE TO PROGYNY’S FERTILITY AND FAMILY BUILDING BENEFIT At Progyny, we know the road to parenthood can be challenging — we were founded by people who’ve faced obstacles to fertility first-hand. That’s why we partner with the nation’s leading fertility specialists to bring you a smarter approach with better care and more successful outcomes. Our benefit is designed so that more options are available to anyone who wants to have a child, no matter their path to parenthood. The Progyny benefit is designed to assist covered employees and their partners who want to have a child, including LGBTQ+ individuals and couples, and single parents by choice. Your benefit also provides coverage for fertility preservation (egg or sperm freezing), which allows you to build a family when you’re ready. We created this guide to provide you with all the information you’ll need to get the most out of your benefit. We understand the journey to become a parent can be physically, emotionally, and financially challenging. With this in mind, we’ve designed your benefit to include comprehensive treatment coverage, access to the highest level of care, and personalized emotional support. We’re here to ensure you have a healthy, timely, and supported family building journey. Personalized Guidance Unlimited guidance and dedicated support from Comprehensive Coverage a patient care advocate throughout your fertility Bundled fertility treatment coverage journey. for every unique path to parenthood. Premier Specialists Convenient access to the largest national network of fertility experts.
  • 13D. OBGYN and Fertility Care for LGBTQIA+ Persons

    13D. OBGYN and Fertility Care for LGBTQIA+ Persons

    Reproductive Care and Obstetrics for LGBTQIA+ Individuals Rebekah P. Viloria MD, FACOG Fenway Health Obstetrics & Gynecology Advancing Excellence in Sexual and Gender Minority Health Conference March 22,2020 DIsclosures ▪ I have no financial disclosures Objective Incorporate reproductive counseling into routine care Understand the potential effects of Gender Affirming Hormone Therapy on fertility Counsel on reproductive choices for family building Clinical Case #1 ▪ 35 y.o. lesbian desiring pregnancy ▪ PMH: Anxiety, BMI 26 ▪ PGynH: No abnormal pap or STI; monogamous with cis female ▪ FH: No birth defects or intellectual disabilities ▪ SH: No alcohol, tobacco, drugs. No recent travel; employed; married Pregnancy ▪ Reciprocal IVF ▪ -partner’s egg + anonymous donor sperm ▪ Aneuploidy testing of embryo ▪ Pan ethnic testing for both patient and partner Antepartum ▪ Immunizations up to date ▪ EPDS=5 ▪ Low risk aneuploidy testing ▪ Normal fetal survey ▪ Normal testing for gestational diabetes ▪ Working with doula ▪ Attended childbirth classes ▪ Created birthing preference plan Delivery ▪ Gestational hypertension at 40 wks ▪ Intrapartum severe hypertension ▪ Cesarean delivery for 2nd stage arrest ▪ Female bodied baby, 8# 2 oz, Apgars 8,9 ▪ Clear drapes ▪ Partner, Skin to skin in OR ▪ Postpartum breastfeeding Family Equality Council (2019) LGBTQ Family Building Survey. https://www.f amilyequality.o rg/fbs Reproductive Wish ▪ Survey of 50 transmen after GRS ▪ 22% participants already had children ▪ 8 had partners conceived with donor sperm ▪ 3 conceived prior to GRS ▪ 54% were interested in having children at time of study ▪ 37.5% would have considered fertility preservation if available ▪ Wierckx K, Van Caenegem E, Pennings G, Elaut E, Dedecker D, Van de Peer F, et al. Reproductive wish in transsexual men.
  • Optimization of Sperm Cryopreservation Protocol for Peregrine Falcon (Falco Peregrinus)

    Optimization of Sperm Cryopreservation Protocol for Peregrine Falcon (Falco Peregrinus)

    animals Article Optimization of Sperm Cryopreservation Protocol for Peregrine Falcon (Falco peregrinus) Beatriz Cardoso 1, Irene Sánchez-Ajofrín 1,* , Cristina Castaño 2, Olga García-Álvarez 1 , Milagros Cristina Esteso 2, Alejandro Maroto-Morales 1, María Iniesta-Cuerda 1 , José Julián Garde 1 , Julián Santiago-Moreno 2 and Ana Josefa Soler 1 1 SaBio IREC (CSIC-UCLM-JCCM), ETSIAM, 02071 Albacete, Spain; [email protected] (B.C.); [email protected] (O.G.-Á.); [email protected] (A.M.-M.); [email protected] (M.I.-C.); [email protected] (J.J.G.); [email protected] (A.J.S.) 2 Department of Animal Reproduction, INIA, 28040 Madrid, Spain; [email protected] (C.C.); [email protected] (M.C.E.); [email protected] (J.S.-M.) * Correspondence: [email protected] Received: 25 March 2020; Accepted: 14 April 2020; Published: 16 April 2020 Simple Summary: The process of semen cryopreservation can have multiple advantages in an ex situ conservation program. However, there is a necessity to adapt the protocol to the specificity of each species. With that in mind, we aimed to optimize the sperm freezing/thawing process and study the effect of different cryoprotectants in the peregrine falcon. Abstract: Sperm cryopreservation is a complex process that needs to be adapted to wild and domestic avian species to ensure proper efficiency. Because of its accessibility, the peregrine falcon may be used as a good model for studying other raptor species. To find the most optimal cryopreservation protocol for peregrine falcon ejaculates, sperm parameters such as motility, viability, DNA fragmentation, acrosome integrity, and mitochondrial activity were analyzed under different conditions by varying the freezing method (slow freezing in straws vs.
  • Examination and Processing of Human Semen

    Examination and Processing of Human Semen

    WHO laboratory manual for the Examination and processing of human semen FIFTH EDITION WHO laboratory manual for the Examination and processing of human semen FIFTH EDITION WHO Library Cataloguing-in-Publication Data WHO laboratory manual for the examination and processing of human semen - 5th ed. Previous editions had different title : WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 1.Semen - chemistry. 2.Semen - laboratory manuals. 3.Spermatozoa - laboratory manuals. 4.Sperm count. 5.Sperm-ovum interactions - laboratory manuals. 6.Laboratory techniques and procedures - standards. 7.Quality control. I.World Health Organization. ISBN 978 92 4 154778 9 (NLM classifi cation: QY 190) © World Health Organization 2010 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications— whether for sale or for noncommercial distribution—should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expres- sion of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specifi c companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
  • Infertility and Fertility Preservation

    Infertility and Fertility Preservation

    Clinical Policy: Infertility and Fertility Preservation Reference Number: CP.PHAR.131 Effective Date: 11.16.16 Last Review Date: 11.19 Coding Implications Line of Business: Commercial, HIM*, HIM-Medical Benefit, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Gonadotropins requiring prior authorization: o Menotropins (Menopur®); follitropin alfa, recombinant (Gonal-f® multi-dose*, Gonal-f® RFF, Gonal-f® RFF Redi-ject); follitropin beta, recombinant (Follistim® AQ); urofollitropin (Bravelle®); choriogonadotropin alfa (Ovidrel®); human chorionic gonadotropin (hCG; generic, Novarel®*, Pregnyl®). Gonadotropin-releasing hormone (GnRH) antagonists requiring prior authorization: o Ganirelex acetate; Cetrorelix (Cetrotide®). ____________ *For Health Insurance Marketplace (HIM), if request is through pharmacy benefit, Gonal-f multi-dose and Novarel is non-formulary and cannot be approved using these criteria; refer to the formulary exception policy, HIM.PA.103. FDA Approved Indication(s) Drugs Indications, Female Indications, Male Drug Name Brand Name Drug Class OI ART HH Prepubertal Cryptorchidism Menotropin Menopur Gonadotropin (hMG x x - FSH and LH) Follitropin alfa, Gonal-f Gonadotropin (FSH) x x x recombinant Follitropin alfa, Gonal-f RFF Gonadotropin (FHS) x x recombinant Follitropin alfa, Gonal-f RFF Gonadotropin (FSH) x x recombinant Redi-ject Follitropin beta, Follistim-AQ Gonadotropin (FSH) x x x recombinant Urofollitropin Bravelle Gonadotropin (FSH)
  • A Protein-Free Extender for Semen Cryopreservation in Wood Bison

    A Protein-Free Extender for Semen Cryopreservation in Wood Bison

    A PROTEIN-FREE EXTENDER FOR SEMEN CRYOPRESERVATION IN WOOD BISON A Thesis Submitted to the College of Graduate and Postdoctoral Studies In Partial Fulfillment of the Requirements For the Degree of Masters of Science In the Department of Veterinary Biomedical Sciences University of Saskatchewan Saskatoon By STEVE YANG © Copyright Steve Yang, July, 2018. All rights reserved. PERMISSION TO USE In presenting this thesis in partial fulfillment of the requirements for a Master degree from the University of Saskatchewan, I agree that the Libraries of this University may take it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work, or, in their absence, by the Head of the Department or the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis. Requests for permission to copy or to make other use of material in this thesis in whole or part should be addressed to: Head of the Department of Veterinary Biomedical Sciences Western College of Veterinary Medicine 52 Campus Drive University of Saskatchewan Saskatoon, Saskatchewan S7N 5B4 Canada OR Dean College of Graduate and Postdoctoral Studies University of Saskatchewan 116 Thorvaldson Building, 110 Science Place Saskatoon, Saskatchewan S7N 5C9 Canada i ABSTRACT Animal proteins are a common constituent of semen extenders to protect sperm from cold shock but they raise issues concerning biosecurity and undefined composition.
  • Sperm Banking

    Sperm Banking

    17 Sperm Banking Rakesh Sharma, Alyssa M. Giroski, and Ashok Agarwal What Is Sperm Banking Autologous and Donor Sperm or Fertility Preservation? Banking for Infertility History of Sperm Banking—50 Years Later Users of sperm banking can be divided into two categories: autologous or autoconservation and donor groups. The autocon- Cryopreservation of human spermatozoa is critical when it comes servation group includes patients who preserve their sperm or to preserving male fertility. While sperm cryopreservation, more testicular tissue for purposes of their own future fertility treat- commonly referred to as sperm freezing or sperm banking, has ment. The donor group includes men who are recruited to serve been prevalent in the scientic community in the treatment of as surrogate fathers to partners of couples suffering from refrac- infertile couples since the 1970s, the origins of sperm cryopreser- tory male infertility problems or for single women planning for vation dates back to as far as the 1660s when Lazzaro Spallanzani a child with donor sperm. These donors elect sperm banking for found that sperm could maintain motility under cold conditions potential use in assisted reproductive techniques (ART). using the invention of Leeuwenhoek’s microscope [1]. Sperm cryopreservation came to be a forerunner in scientic studies after the development of articial insemination and the grow- ing need for longer-term storage of bull sperm in the US dairy Sperm Banking in Patients with Cancer industry in the late 1950s to early 1960s. This period of time saw signicant growth in the studies on sperm biology, morphology, In the United States, up to 9.2% of patients diagnosed with cancer and cryobiology [2].
  • Background on Fertility Preservation

    Background on Fertility Preservation

    California Health Benefits Review Program Analysis of California Senate Bill 172 Fertility Preservation A Report to the 2017-2018 California State Legislature April 13, 2017 Key Findings: Analysis of California Senate Bill 172 Fertility Preservation Summary to the 2017-2018 California State Legislature, April 13, 2017. CONTEXT AT A GLANCE Iatrogenic infertility is medically induced infertility caused by a medical intervention that treats a primary disease or As introduced, Senate Bill (SB) 172 would require that condition.1 If a patient anticipates a treatment that could individual or group health care service plans or policies shall increase the risk of iatrogenic infertility, the patient and include coverage for standard fertility preservation services when a necessary medical treatment may cause iatrogenic their provider may pursue fertility preservation services infertility. As amended (March 7, 2017), the bill would require prior to the treatment. The National Cancer Institute coverage for evaluation and treatment of iatrogenic infertility defines fertility preservation as a type of procedure used including but not limited to standard fertility preservation to maintain an individual’s ability to have children. services. The cost section of this report estimates impacts of both the introduced and amended language. However, the rest of the report reflects only the language as introduced. BILL SUMMARY 1. CHBRP estimates that, in 2018, of the approximately 24 million Californians enrolled in state-regulated health As introduced (January 23, 2017), Senate Bill (SB) 172 insurance, 16.2 million will have insurance subject to SB would require that individual or group health care service 172. plans or policies issued, amended, or renewed on and 2.
  • Fertility Preservation Outcomes in Adolescent and Young Adult Feminizing Transgender Patients Emily P

    Fertility Preservation Outcomes in Adolescent and Young Adult Feminizing Transgender Patients Emily P

    Fertility Preservation Outcomes in Adolescent and Young Adult Feminizing Transgender Patients Emily P. Barnard, DO,a Cherie Priya Dhar, MD,b Stephanie S. Rothenberg, MD,a Marie N. Menke, MD,a Selma F. Witchel, MD,b Gerald T. Montano, DO,b Kyle E. Orwig, PhD,c Hanna Valli-Pulaski, PhDc BACKGROUND: Fertility preservation enables patients undergoing gonadotoxic therapies to retain abstract the potential for biological children and now has broader implications in the care of transgender individuals. Multiple medical societies recommend counseling on fertility preservation before initiating therapy for gender dysphoria; however, outcome data pre- and posttreatment are limited in feminizing transgender adolescents and young adults. METHODS: The University of Pittsburgh Institutional Research Board approved this study. Data were collected retrospectively on transgender patients seeking fertility preservation between 2015 and 2018, including age at initial consultation and semen analysis parameters. RESULTS: Eleven feminizing transgender patients accepted a referral for fertility preservation during this time; consultation occurred at median age 19 (range 16–24 years). Ten patients attempted and completed at least 1 semen collection. Eight patients cryopreserved semen before initiating treatment. Of those patients, all exhibited low morphology with otherwise normal median semen analysis parameters. In 1 patient who discontinued leuprolide acetate to attempt fertility preservation, transient azoospermia of 5 months’ duration was demonstrated with subsequent recovery of spermatogenesis. In a patient who had previously been treated with spironolactone and estradiol, semen analysis revealed persistent azoospermia for the 4 months leading up to orchiectomy after discontinuation of both medications. CONCLUSIONS: Semen cryopreservation is a viable method of fertility preservation in adolescent and young adult transgender individuals and can be considered in patients who have already initiated therapy for gender dysphoria.
  • Serious Impact of Deficiency of Liquid Nitrogen in Cryogenic Containers

    Serious Impact of Deficiency of Liquid Nitrogen in Cryogenic Containers

    : In OPEN ACCESS Freely available online tion Vit iza ro il -I rt V e F - F W f o o r l l d a Journal of Fertilization: In vitro - IVF-Worldwide, w n r i d u e o J ISSN: 2375-4508 Reproductive Medicine, Genetics & Stem Cell Biology Short Communication Serious Impact of Deficiency of Liquid Nitrogen in Cryogenic Containers and Quality Control for Preservation of Gametes and Embryos Aya Al-Ibraheemi1,2*, Mustafa Zakaria3,4*, Wassym R. Senhaji5, Mohamed Zarqaoui4,6,7, Romaissa Boutiche8,9, Mohammed Ennaji4,10, Ritu S. Santwani4,11, Valeria E. Canada12,13, Noureddine Louanjli14, Abdelhafid Natiq4,15 1Department ofEmbryology, University of Nottingham, UK; 2Scientific Research Group, Art Irifiv Scientific Research Group (AISRG) United Kingdom; 3Department of Reproductive Biology, and Assisted Reproductive Technology, Northwestern University,Evanston, Illinois, USA; 4IRIFIV Fertility Center - ART IRIFIV Scientific Research Group (AISRG), Casablanca, Morocco; 5Department of Gynecology and Obstetrics, Endoscopy and Fertility, IRIFIV Fertility Center - ART IRIFIV Scientific Research Group (AISRG) Casablanca, Morocco; 6Department ofEndoscopic Surgery Obstetrics and Gynecology, Strasbourg University Medicine Pole, Strasbourg, Alsace-Champagne- Ardenne-, France; 7Department of Gynecology and Obstetrics, IRIFIV Fertility Center, Casablanca, Morocco; 8Department of Clinical Embryology, IVF Laboratory, Rota by Fertility Center, Algeria; 9Scientific Research Group - Art Irifiv Scientific Research Group (AISRG), Algeria; 10Department of Embryology, IRIFIV
  • Fertility Tests Diagnostics Laboratory Charges Basic Semen Analysis £100.00 Timelapse Incubation (Embryoscope)◊◊◊ £788.00

    Fertility Tests Diagnostics Laboratory Charges Basic Semen Analysis £100.00 Timelapse Incubation (Embryoscope)◊◊◊ £788.00

    Date of Baseline / Test / Freeze / Annual Storage __________________________ Fertility Tests Diagnostics Laboratory Charges Basic Semen Analysis £100.00 Timelapse incubation (EmbryoScope)◊◊◊ £788.00 Basic Semen Analysis + Antisperm Antibody (ASA) Test £122.00 Blastocyst culture £387.00 Semen Analysis with Swim Up £132.00 Initial Embryo Cryopreservation £387.00 Semen Analysis with Swim Up & ASA Test £163.00 Additional Embryo Cryopreservation (within same £193.00 treatment cycle) Antisperm Antibody (ASA) Test £28.00 Annual Storage for sperm , eggs or embryos £193.00 Post-Vasectomy Semen Analysis £50.00 Sperm storage consultation and test freeze £404.00 24 Hour Sperm Culture £39.00 Egg Freeze/Vitrification £2,356.00 Ultrasound Follicle Tracking (Clomid etc) Inc *** scans £331.00 Semen Cryopreservation^ £171.00 Scan x 1 £110.00 Vasectomy Reversal in RSH Theatres £566.00 Donor/Shared Egg Charges Scientific Consultation £39.00 Non Refundable Booking Charge - Recipient £711.00 Admin Charge £132.00 Shared Egg Recipient - 1st IVF◊ £4,781.00 Donor Sperm Costs (can vary depending on donor supplier) Shared Egg Recipient - 1st ICSI◊ £5,640.00 Centre Stored Donor Sperm (per ampoule) £276.00 Shared Egg Recipient Subsequent IVF◊◊ £4,649.00 Donor Sperm Block Booking Shared Egg Recipient Subsequent ICSI◊◊ £5,508.00 Annual Sibling Sperm Storage £193.00 Egg Sharer First IVF £1,328.00 Other Costs Egg Sharer First ICSI £1,911.00 Counselling Session £44.00 Egg Sharer Subsequent IVF £1,196.00 Donor Egg Screening Package (incl. 1st & 2nd £610.16 screening below)